Study: NCT00525876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Matched Donors:~750 mg/m\^2 given intravenously on Day -3, 4 hours after completion of Fludarabine.~Unrelated or Mismatched Donors:~1000 mg/m\^2 given intravenously on Day -3, 4 hours after completion of Fludarabine.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Matched Donors:~750 mg/m\^2 given intravenously on Day -3, 4 hours after completion of Fludarabine.~Unrelated or Mismatched Donors:~1000 mg/m\^2 given intravenously on Day -3, 4 hours after completion of Fludarabine.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 given intravenously on Days -5 and -3 before transplantation.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 given intravenously on Days -5 and -3 before transplantation.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Matched Donors:~375 mg/m\^2 given intravenously on Days -13, -6 before transplantation and Days 16, 8 after transplantation.~Unrelated/Mismatched Donors:~375 mg/m\^2 given intravenously on Days -8, -1 before transplantation and Days 6, 13 after transplantation.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)~For development of disease progression or no response, immunomanipulation with Rituximab 375 mg/m\^2 given intravenously, then 1000 mg/m\^2 given intravenously weekly for 3 weeks, and taper off Tacrolimus dose over 2 weeks.~DLI = Donor Lymphocyte Infusion/Immunomodulation Post Transplantation Immunomodulation for patients with lymphoid Malignancies:~375 mg/m\^2 then 1000 mg/m\^2 weekly x 3 if immunomanipulation is undertaken for persistent disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Matched Donors:~375 mg/m\^2 given intravenously on Days -13, -6 before transplantation and Days 16, 8 after transplantation.~Unrelated/Mismatched Donors:~375 mg/m\^2 given intravenously on Days -8, -1 before transplantation and Days 6, 13 after transplantation.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)~For development of disease progression or no response, immunomanipulation with Rituximab 375 mg/m\^2 given intravenously, then 1000 mg/m\^2 given intravenously weekly for 3 weeks, and taper off Tacrolimus dose over 2 weeks.~DLI = Donor Lymphocyte Infusion/Immunomodulation Post Transplantation Immunomodulation for patients with lymphoid Malignancies:~375 mg/m\^2 then 1000 mg/m\^2 weekly x 3 if immunomanipulation is undertaken for persistent disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Unrelated/Mismatched Donors:~15 mg per day given intravenously days 1 through 3 after transplantation.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Stem Cell Infusion
Description: Infusion of stem cells.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Stem Cell Infusion
Description: Infusion of stem cells.